A Milestone in mRNA Vaccine History

Moderna's (MRNA) respiratory syncytial virus (RSV) mRNA vaccine, mResvia (generic: mRNA-1345), received final marketing authorization from the European Medicines Agency (EMA) on August 23, 2024. This marks the second instance of an mRNA platform technology receiving regulatory approval for commercialization beyond COVID-19 vaccines, and it holds symbolic significance as the first RSV mRNA vaccine in the European market. This approval further validates the effectiveness of mRNA technology, which is designed to induce a robust immune response by targeting the RSV F protein precursor (pre-fusion F glycoprotein).

Compelling Data from the ConquerRSV Phase 3 Trial

The Phase 3 ConquerRSV study, which served as the basis for this EMA approval, was conducted in 22 countries worldwide and involved approximately 37,000 individuals aged 60 and older. The clinical results demonstrated that mResvia achieved an excellent vaccine efficacy (VE) of 83.7% against RSV-related lower respiratory tract disease (LRTD) with two or more symptoms, fully meeting the primary endpoint. Furthermore, the safety profile was favorable, with only mild adverse events such as injection site pain or fatigue, confirming that it can be a safe and reliable prevention option for older adults.

Differentiated Competitive Advantage with Pre-filled Syringe Formulation

The European RSV vaccine market is currently dominated by GSK's Arexvy and Pfizer's (PFE) Abrysvo, creating a highly competitive landscape. Unlike these competing drugs, mResvia is uniquely available in a pre-filled syringe formulation, allowing for immediate administration without the need for separate dilution or preparation on-site. This convenience eliminates the potential for medication errors by healthcare professionals and significantly reduces the time required for administration, making it a strong factor in large-scale vaccination campaigns.

Market Size and Commercial Prospects for RSV Vaccines

The global RSV vaccine market is projected to grow rapidly to approximately $10 billion by 2030, and Arexvy and Abrysvo combined recorded sales of over $2 billion in their first commercial year in 2023. With this EMA approval, Moderna has secured the legal right to participate in pricing and reimbursement listings and government procurement tenders in the 27 member states of Europe and other territories. While the pace of securing public health budgets and applying subsidies in each country will be a key variable in future commercial success, long-term revenue growth is virtually assured, driven by the increasing population of older adults who are vulnerable to infection.

Future Prospects: Expanding Indications and Platform Advancement

Building on this approval for older adults, Moderna is accelerating subsequent clinical studies to expand indications to high-risk adult populations aged 18 to 59 and infants. Furthermore, the company is also visualizing a strategy to link this success with its next-generation pipeline, including the development of a combination mRNA vaccine that can prevent both influenza and RSV. This commercial success is seen as a positive sign that will increase the success rate of Moderna's various mRNA-based pipelines in clinical trials, including cancer vaccines and treatments for rare diseases.